BACKGROUNDTriple-unfavorable breast most cancers (TNBC) is highly aggressive with an elevated metastatic incidence as compared to other breast cancer subtypes. Having said that, due to absence of clinically trustworthy biomarkers and qualified therapy in TNBC, outcomes are suboptimal. For this reaso